{"id":"camrelizumab-apatinib-eribulin","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related adverse events (fatigue, rash, hepatotoxicity)"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL1683590","moleculeType":"Small molecule","molecularWeight":"729.91"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Camrelizumab is a PD-1 inhibitor that restores T-cell-mediated anti-tumor immunity by blocking the PD-1/PD-L1 axis. Apatinib is a tyrosine kinase inhibitor targeting VEGFR-2 that suppresses tumor angiogenesis and vascular endothelial growth. Eribulin is a microtubule dynamics inhibitor that disrupts mitotic spindle formation and induces apoptosis in cancer cells. The triple combination aims to synergistically attack tumors through immune activation, anti-angiogenesis, and direct cytotoxicity.","oneSentence":"This combination therapy enhances anti-tumor immunity by blocking PD-1 checkpoint inhibition while simultaneously inhibiting angiogenesis and disrupting microtubule dynamics to suppress tumor growth.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:44.081Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic breast cancer (phase 3 investigation)"}]},"trialDetails":[{"nctId":"NCT06889688","phase":"PHASE3","title":"Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-04-01","conditions":"Breast Cancer Stage IV","enrollment":246},{"nctId":"NCT04303741","phase":"PHASE2","title":"A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2020-03-25","conditions":"Breast Cancer","enrollment":46}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Camrelizumab+Apatinib+Eribulin","genericName":"Camrelizumab+Apatinib+Eribulin","companyName":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","companyId":"sun-yat-sen-memorial-hospital-of-sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination therapy enhances anti-tumor immunity by blocking PD-1 checkpoint inhibition while simultaneously inhibiting angiogenesis and disrupting microtubule dynamics to suppress tumor growth. Used for Advanced or metastatic breast cancer (phase 3 investigation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}